文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

多黏菌素B固定化血液灌流与脓毒症/脓毒性休克危重成人患者死亡率:系统评价、Meta分析与试验序贯分析

Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis.
PubMed 文献 · Intensive Care Med · 2017-12-04
一句话结论低确定性证据显示,PMX-HP不降低脓毒症或脓毒性休克危重成人28天死亡率(RR 1.03,95%CI 0.78-1.36),目前证据不足以支持常规使用。

该系统评价纳入6项随机对照试验共857例脓毒症或脓毒性休克危重成人(加权平均年龄62.5岁),评估多黏菌素B固定化血液灌流(PMX-HP)的疗效与安全性。PMX-HP组28天全因死亡率的合并RR为1.03(95%CI 0.78-1.36;I²=25%;n=797),至少发生一次严重不良事件的合并RR为2.17(95%CI 0.68-6.94;I²=0%;n=717),24-72小时器官功能障碍评分无显著变化(SMD -0.26;95%CI -0.64至0.12;I²=78%;n=797)。GRADE评价显示获益与危害的证据确定性均为低。作者结论为目前证据不足以支持PMX-HP常规用于脓毒症或脓毒性休克患者。

要点

  • PMX-HP不降低28天全因死亡率:合并RR 1.03(95%CI 0.78-1.36;I²=25%;n=797),证据确定性低。
  • 严重不良事件合并RR 2.17(95%CI 0.68-6.94;I²=0%;n=717),置信区间宽且跨1,未达统计学显著。
  • 24-72小时器官功能障碍评分无显著改善:SMD -0.26(95%CI -0.64至0.12;I²=78%;n=797)。
  • GRADE评价获益与危害的证据确定性均为低,作者结论为证据不足以支持常规使用PMX-HP。
  • 共纳入6项RCT、857例脓毒症或脓毒性休克危重成人,加权平均年龄62.5岁。

适用人群与场景

  • 脓毒症或脓毒性休克的危重成人患者(6项RCT共857例,加权平均年龄62.5岁)。

研究设计与关键结果

  • 研究类型:系统评价、Meta分析与试验序贯分析,纳入6项随机对照试验(857例参与者,加权平均年龄62.5岁)。
  • 主要终点28天全因死亡率:PMX-HP合并RR 1.03(95%CI 0.78-1.36;I²=25%;n=797)。
  • 至少发生一次严重不良事件:合并RR 2.17(95%CI 0.68-6.94;I²=0%;n=717)。
  • PMX-HP治疗后24-72小时器官功能障碍评分:SMD -0.26(95%CI -0.64至0.12;I²=78%;n=797),无显著变化。
  • GRADE评价:获益与危害的证据确定性均判定为低。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入6项随机对照试验,采用GRADE方法评价证据确定性。
  • 证据确定性:获益与危害均为低(GRADE)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:目前证据不足以支持PMX-HP常规用于脓毒症或脓毒性休克患者。

指南或共识出处

  • PROSPERO国际前瞻性系统评价注册库(CRD42016038356)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Polymyxin B-immobilized hemoperfusion (PMX-HP) is an adjuvant therapy for sepsis or septic shock that clears circulating endotoxin. Prior trials have shown that PMX-HP improves surrogate endpoints. We aimed to conduct an evidence synthesis to evaluate the efficacy and safety of PMX-HP in critically ill adult patients with sepsis or septic shock.

METHODS: We searched for randomized controlled trials (RCTs) in MEDLINE, EMBASE, the Cochrane Library, the Health Technology Assessment Database, CINAHL, "Igaku Chuo Zasshi", the National Institute of Health Clinical Trials Register, the World Health Organization International Clinical Trials Registry Platform, the University Hospital Medical Information Network Clinical Trials Registry, the reference lists of retrieved articles, and publications by manufacturers of PMX-HP. The primary outcomes were 28-day all-cause mortality, the number of patients with at least one serious adverse event, and organ dysfunction scores. The GRADE methodology for the certainty of evidence was used.

RESULTS: Six trials (857 participants; weighted mean age 62.5 years) proved eligible. Patient-oriented primary outcomes were assessed. The pooled risk ratio (RR) for 28-day mortality associated with PMX-HP was 1.03 [95% confidence interval (CI) 0.78-1.36; I 2 = 25%; n = 797]. The pooled RR for adverse events was 2.17 (95% CI 0.68-6.94; I 2 = 0%; n = 717). Organ dysfunction scores over 24-72 h after PMX-HP treatment did not change significantly (standardized mean difference - 0.26; 95% CI - 0.64 to 0.12; I 2 = 78%; n = 797). The certainty of the body of evidence was judged as low for both benefit and harm using the GRADE methodology.

CONCLUSIONS: There is currently insufficient evidence to support the routine use of PMX-HP to treat patients with sepsis or septic shock.

REGISTRATION: PROSPERO International Prospective Register of Systematic Reviews (CRD42016038356).

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Fujii T, Ganeko R, Kataoka Y, et al. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2017. PMID: 29204670. doi:10.1007/s00134-017-5004-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。